In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, discuss summertime illnesses and key insights from a recent diagnostic investment event. Together, they explore:

Common summertime illnesses, along with tips for prevention.

• How investment in diagnostic tools influences innovation in the laboratory.
• The potential impact of growing interest in AI investments.
• The investment interest in liquid biopsy and its potential implications for clinical decision-making.
• How AI development may accelerate adoption of mass spectrometry, proteomics, and similar advancements in clinical laboratories.

Linda Hasadsri, M.D., Ph.D., and Huong Cabral, M.S., CGC, explain how Mayo Clinic Laboratories' expanded test panel captures rarer as well as more common genetic causes of hereditary pancreatitis. That information is key to managing patients' enhanced risk for pancreatic cancer.

Speaker 4: (00:32)
Could you both please tell us a little bit about yourself and your background?

Speaker 4: (02:23)
Could you please give the audience a brief overview of this assay?

Speaker 4: (03:53)
Which patients should have this test, and when should it be performed?

Speaker 4: (04:49)
What alternative testing options are available, and how do these compare to the new, expanded panel that we're going to be offering?

Speaker 4: (08:20)

How are the results used in patient care?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, share insights from industry news and recent conferences, including PlatforMed. They explore:

• The significant interest in diagnostics for the advancement of cancer care.
• The Joint Commission’s collaboration with the Coalition for Health AI to establish guidelines for the responsible use of artificial intelligence.
• The growing understanding that platforms offer an opportunity to expand access and make knowledge more accessible as platform-driven solutions become a reality.
• The role of laboratorians in guiding the ethical and effective use of data and emerging technologies — and what this means for educating future healthcare professionals.
• The critical importance of values and ethics in deploying new tools.

Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' labile copper assay (Mayo ID: LBCS) improves upon standard blood tests for Wilson's disease. The new test measures not just overall copper but also the fraction of copper that is bioavailable, or labile bound.

(00:32)
Can you tell us a little bit about yourself and your background?

(01:33)
Could you give us a brief overview of this assay?

(02:47)
Which patients should have this testing, and when should it be performed?

(03:48)
How would the results be used in patient care?

John Lieske, M.D., and Sandra Taler, M.D., explain how Mayo Clinic Laboratories' mass spectrometry assay helps evaluate patients for resistant hypertension. The test detects antihypertensive medications in urine, providing evidence of whether patients are absorbing their medications or whether a new treatment approach might be needed.

Speaker 3: (00:33)
Could you tell us a little about yourselves and your backgrounds?

Speaker 3: (01:41)
Dr. Taler, could you provide us with a brief background on resistant hypertension?

Speaker 3: (03:43)
Can you provide a little bit more background on patients who aren't taking their medications?

Speaker 3: (05:11)
How do physicians currently assess whether patients are taking their medications?

Speaker 3: (07:03)
Dr. Lieske, could you tell us how this new assay can be used to help physicians manage their patients with hypertension?

Speaker 3: (09:43)
Dr. Taler, can you tell us how doctors can use this new testing to manage their patients?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and Div Dubey, M.B.B.S., a neurologist and co-director of the Clinical Neuroimmunology Laboratory at Mayo Clinic, explore the topic of peripheral neuropathy. Their discussion covers:

• The high prevalence of peripheral neuropathy and why early diagnosis is important.
• The complexities involved in diagnosing the condition.
• Symptoms that should prompt clinicians to order advanced testing early in the diagnostic process.
• How algorithms are enhancing the use of testing to complement other diagnostic tools.
• Ongoing discovery related to specific antibodies associated with neuropathies.

Learn more in our e-book, "Peripheral neuropathy: Cutting through diagnostic dissonance with an algorithmic approach."

Joseph Yao, M.D., explains how Mayo Clinic Laboratories' new quantitative assay (Mayo ID: ADVQU) goes beyond qualitative testing to evaluate transplant patients for adenovirus infection. Adenovirus can cause life-threatening disease in immunocompromised transplant patients, especially children.

(01:14)
Could you give us a brief overview of this assay?

(02:06)
Can you explain the differences of the qualitative and quantitative methods and why we made the change to a quantitative adenovirus method?

(04:00)
When is this test typically ordered for transplant patients? Is it used throughout their treatment?

(06:56)

Could an immunocompromised person be unknowingly infected?

(07:31)

Is our quantitative method approved for pediatric patients?

(08:00)

How are the test results used to treat patients?

(10:36)

What other infections might providers consider alongside adeovirus?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, discuss global trends in diagnostic manufacturing and their implications for laboratory professionals. Topics include:

• Emerging innovations in mass spectrometry, next-generation sequencing, automation, and artificial intelligence.
• Fierce competition in the global manufacturing landscape as new companies enter the market.
• Geopolitical dynamics influencing where innovations are deployed.
• Why laboratory professionals need to drive innovation implementation to maximize benefits for clinicians and their patients.